Showing results (21-30 of 86) with videos related to

Sort By:
Pageof 9
Future Oncology (London, England)|April 9, 2010
Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Ryuichi Kanai, Hiroaki Wakimoto, Tooba Cheema, et al.
Oncoimmunology|March 26, 2019
Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockadePraveen K Bommareddy, Samuel D Rabkin, Howard L Kaufman
American Journal of Cancer Research|May 18, 2016
Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastomaShinichi Esaki, Samuel D Rabkin, Robert L Martuza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2011
A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cellsRyuichi Kanai, Hiroaki Wakimoto, Robert L Martuza, et al.
BMC Biotechnology|September 26, 2006
Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinasesToshihiko Kuroda, Robert L Martuza, Tomoki Todo, et al.
International Journal of Oncology|November 24, 2011
Oncolytic herpes simplex virus treatment of metastatic breast cancerJiani Wang, Pan Hu, Musheng Zeng, et al.
Viruses|September 28, 2021
In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSVNusrat Jahan, Shanawaz M Ghouse, Robert L Martuza, et al.
Oncoimmunology|February 28, 2014
Immunovirotherapy for the treatment of glioblastomaTooba A Cheema, Peter E Fecci, Jianfang Ning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeuticsTa-Chiang Liu, Hiroaki Wakimoto, Robert L Martuza, et al.
Oncoimmunology|May 31, 2019
Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanomaPraveen K Bommareddy, Andrew Zloza, Samuel D Rabkin, et al.
Pageof 9